|
Enlarge font
Reduce font
ObCure’s drug expected to reach market in 2007
ObCure bought the rights to the drug from a Clalit Health Services company for $75,000, plus royalties and payments for milestones.
Gali Weinreb1 Dec 05 13:00
For the whole article please click here.
|
 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
feeds
HomeMarket prices | Site map | Newsletters | Israel links | About us | Support | Report Faults | Advertise | Archive | 
Home | News | Analysis | Features | Technology guide | Real estate | Israel in depth | International
Application delivery by 